Risk factors for interstitial lung disease in rheumatoid arthritis: a cohort study from the KOBIO registry

被引:2
作者
Min, Hong Ki [1 ]
Kim, Se Hee [1 ,2 ]
Lee, Sang-Heon [3 ]
Kim, Hae-Rim [4 ]
机构
[1] Konkuk Univ, Med Ctr, Dept Internal Med, Div Rheumatol, Seoul, South Korea
[2] Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Coll Med, Dept Rheumatol, Seoul, South Korea
[3] Konkuk Univ, Sch Med, Res Inst Med Sci, Div Rheumatol,Dept Internal Med,Med Ctr, Seoul, South Korea
[4] Konkuk Univ, Sch Med, Med Ctr, Div Rheumatol,Dept Internal Med,Res Inst Med Sci, 120-1 Neungdong Ro, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
biologics; DAS28; DMARDs; interstitial lung disease; rheumatoid arthritis; rheumatoid factor; AMERICAN-COLLEGE; EPIDEMIOLOGY; ABATACEPT; EVENTS;
D O I
10.1177/1759720X231218098
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Interstitial lung disease (ILD) is a critical extra-articular manifestation of rheumatoid arthritis (RA). However, little is known about the risk factors of RA-ILD.Objectives: Here, we examined the effect of demographic, clinical, therapeutic, and environmental factors on the incidence of ILD in RA patients using the Korean College of Rheumatology Biologics and Targeted Therapy (KOBIO) registry.Design: We used data from the KOBIO registry, a multi-center, prospective, observational cohort that included RA patients in South Korea.Methods: RA patients who used biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) or conventional synthetic (cs)DMARDs, and were enrolled in the KOBIO registry, were examined. Demographic, clinical, and radiographic characteristics, as well as medications, were recorded at baseline and annually thereafter. Kaplan-Meier curves and the log-rank test were used to compare the incidence of ILD between RA patients taking different b/tsDMARDs. Hazard ratios (HRs) were calculated by Cox regression analyses.Results: In total, 2492 patients (1967 in the b/tsDMARDs group and 525 in the csDMARDs group) were analyzed. The b/tsDMARDs group showed longer disease duration, higher erythrocyte sedimentation rate/C-reactive protein, and higher disease activity score-28 (DAS28) than the csDMARDs group. The incidence of ILD was significantly higher in those taking tumor necrosis factor inhibitors and abatacept than in those taking csDMARDs (log ranked p < 0.001). Multivariate Cox regression analysis identified older age (HR = 1.057, p = 0.001), male sex (HR = 2.824, p = 0.007), time-averaged DAS28 (HR = 2.241, p < 0.001), and rheumatoid factor titer (HR = 1.009, p = 0.007) as having a significantly increased HR for ILD occurrence.Conclusion: ILD is a rare but critical extra-articular symptom of RA patients. Therefore, RA patients with the above risk factors should be monitored carefully for ILD development.
引用
收藏
页数:12
相关论文
共 50 条
[21]   Genetic, social, and environmental risk factors in rheumatoid arthritis-associated interstitial lung disease [J].
Wheeler, Austin M. ;
Baker, Joshua F. ;
Poole, Jill A. ;
Ascherman, Dana P. ;
Yang, Yangyuna ;
Kerr, Gail S. ;
Reimold, Andreas ;
Kunkel, Gary ;
Cannon, Grant W. ;
Wysham, Katherine D. ;
Singh, Namrata ;
Lazaro, Deana ;
Monach, Paul ;
Bridges, S. Louis ;
Mikuls, Ted R. ;
England, Bryant R. .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2022, 57
[22]   Analysis of comorbidity in rheumatoid arthritis-associated interstitial lung disease: a nested case-cohort study [J].
Mena-Vazquez, Natalia ;
Rojas-Gimenez, Marta ;
Maria Romero-Barco, Carmen ;
Gandia-Martinez, Myriam ;
Perez-Gomez, Nair ;
Javier Godoy-Navarrete, Francisco ;
Manrique-Arija, Sara ;
Garcia-Studer, Aimara ;
Calvo-Gutierrez, Jerusalem ;
Fuego Varela, Clara ;
Morales-Garrido, Pilar ;
Castro Perez, Patricia ;
Mourino-Rodriguez, Coral ;
Anon-Onate, Isabel ;
Espildora, Francisco ;
Carmen Aguilar-Hurtado, Maria ;
Redondo, Rocio ;
Hidalgo Conde, Ana ;
Diez de los Rios, Rocio Arnedo ;
Cabrera Cesar, Eva ;
Luisa Velloso-Feijoo, Maria ;
Fernandez-Nebro, Antonio .
BIOMEDICINE & PHARMACOTHERAPY, 2023, 157
[23]   Targeted Therapy in Rheumatoid-Arthritis-Related Interstitial Lung Disease [J].
Harrington, Robert ;
Harkins, Patricia ;
Conway, Richard .
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (20)
[24]   Protective effect of methotrexate on lung function and mortality in rheumatoid arthritis-related interstitial lung disease: a retrospective cohort study [J].
Kim, Kangjoon ;
Woo, Ala ;
Park, Youngmok ;
Yong, Seung Hyun ;
Lee, Su Hwan ;
Lee, Sang Hoon ;
Leem, Ah Young ;
Kim, Song Yee ;
Chung, Kyung Soo ;
Kim, Eun Young ;
Jung, Ji Ye ;
Kang, Young Ae ;
Kim, Young Sam ;
Park, Moo Suk .
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
[25]   Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients [J].
Fernandez-Diaz, Carlos ;
Loricera, Javier ;
Castaneda, Santos ;
Lopez-Mejias, Raquel ;
Ojeda-Garcia, Clara ;
Olive, Alejandro ;
Rodriguez-Muguruza, Samantha ;
Carreira, Patricia E. ;
Perez-Sandoval, Trinidad ;
Retuerto, Miriam ;
Cervantes-Perez, Evelin C. ;
Flores-Robles, Bryan J. ;
Hernandez-Cruz, Blanca ;
Urruticoechea, Ana ;
Maiz-Alonso, Olga ;
Arboleya, Luis ;
Bonilla, Gema ;
Hernandez-Rodriguez, Inigo ;
Palma, Desiree ;
Delgado, Concepcion ;
Exposito-Molinero, Rosa ;
Ruibal-Escribano, Ana ;
Alvarez-Rodriguez, Belen ;
Blanco-Madrigal, Juan ;
Bernal, Jose A. ;
Vela-Casasempere, Paloma ;
Rodriguez-Gomez, Manuel ;
Fito, Concepcion ;
Ortiz-Sanjuan, Francisco ;
Narvaez, Javier ;
Moreno, Manuel ;
Lopez-Corbeto, Mireia ;
Mena-Vazquez, Natalia ;
Aguilera-Cros, Clara ;
Romero-Yuste, Susana ;
Ordonez, Sergi ;
Villa-Blanco, Ignacio ;
Carmen Gonzelez-Vela, M. ;
Mora-Cuesta, Victor ;
Palmou-Fontana, Natalia ;
Hernandez, Jose L. ;
Gonzalez-Gay, Miguel A. ;
Blanco, Ricardo .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 48 (01) :22-27
[26]   Impact of concomitant methotrexate on disease activity in patients with rheumatoid arthritis tapering abatacept: results from KOBIO registry [J].
Park, Jun Won ;
Kim, Ju Yeon ;
Kim, Min Jung ;
Lim, Yoo Kyoung ;
Kim, Hyoun-Ah ;
Kim, Jin Hyun ;
Shin, Kichul .
FRONTIERS IN MEDICINE, 2024, 11
[27]   Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry [J].
Park, Dong-Jin ;
Choi, Sung Jae ;
Shin, Kichul ;
Kim, Hyoun-Ah ;
Park, Yong-Beom ;
Kang, Seong Wook ;
Kwok, Seung-Ki ;
Kim, Seong-Kyu ;
Nam, Eon Jeong ;
Sung, Yoon-Kyoung ;
Lee, Jaejoon ;
Lee, Chang Hoon ;
Jeon, Chan Hong ;
Lee, Shin-Seok .
CLINICAL RHEUMATOLOGY, 2017, 36 (05) :1013-1022
[28]   Serum alarmins and the risk of incident interstitial lung disease in rheumatoid arthritis [J].
Poole, Jill A. ;
England, Bryant R. ;
Sayles, Harlan ;
Johnson, Tate M. ;
Duryee, Michael J. ;
Hunter, Carlos D. ;
Baker, Joshua F. ;
Kerr, Gail S. ;
Kunkel, Gary ;
Cannon, Grant W. ;
Sauer, Brian C. ;
Wysham, Katherine D. ;
Joseph, Amy M. ;
Wallace, Beth I. ;
Thiele, Geoffrey M. ;
Mikuls, Ted R. .
RHEUMATOLOGY, 2023, 63 (07) :1998-2005
[29]   Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study [J].
Manfredi, Andreina ;
Cassone, Giulia ;
Furini, Federica ;
Gremese, Elisa ;
Venerito, Vincenzo ;
Atzeni, Fabiola ;
Arrigoni, Eugenio ;
Della Casa, Giovanni ;
Cerri, Stefania ;
Govoni, Marcello ;
Petricca, Luca ;
Iannone, Florenzo ;
Salvarani, Carlo ;
Sebastiani, Marco .
INTERNAL MEDICINE JOURNAL, 2020, 50 (09) :1085-1090
[30]   Implications of Persistent Pain in Patients With Rheumatoid Arthritis Despite Remission Status: Data From the KOBIO Registry [J].
Kim, Hyoun-Ah ;
Park, So Young ;
Shin, Kichul .
JOURNAL OF RHEUMATIC DISEASES, 2022, 29 (04) :215-222